Efpeglenatide is a GLP-1 receptor agonist under development for type 2 diabetes, obesity, and reduction of cardiovascular risk in these populations. It is developed by Hanmi Pharmaceutical. The product remains investigational per listed legal status.
ACT Capital Management invested $7.25 million in Viking Therapeutics as the company advances its obesity drug candidate VK2735 into Phase 3 trials. India's drug regulator warned pharmaceutical companies against direct or surrogate advertising of weight-loss medicines, while South Korean drugmakers target year-end commercialization of domestically developed obesity treatments.
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03684642 |
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin |
TERMINATED | PHASE3 |
